Myocardial microRNAs associated with reverse remodeling in human heart failure

Abstract

NIH 2R01 HL48013, 1R01 HL71118 (Bristow, PI); sponsored research agreements from Glaxo-SmithKline and AstraZeneca (Bristow, PI); NIH P20 HL101435 (Lowes, Port multi-PD/PI); sponsored research agreement from Miragen Therapeutics (Port, PI).

Lycium barbarum polysaccharides restore adverse structural remodelling and cardiac contractile dysfunction induced by overexpression of microRNA‐1

“…Recently, constituents from natural herbs have attracted attention with regard to pharmaceutical development. MicroRNA (miRNA), a small non‐coding RNA, is emerged as a critical node in post‐transcriptional regulation and a newly discovered class of gene regulatory factors at the core of human physiology and disease 3, 4. Increasing lines of evidence have been rapidly evolving for the crucial roles of miRNAs in regulating diverse aspects of cardiac function and progression of HF 4, 5.…”

“…MicroRNA (miRNA), a small non‐coding RNA, is emerged as a critical node in post‐transcriptional regulation and a newly discovered class of gene regulatory factors at the core of human physiology and disease 3, 4. Increasing lines of evidence have been rapidly evolving for the crucial roles of miRNAs in regulating diverse aspects of cardiac function and progression of HF 4, 5. And notably microRNA‐1 (miR‐1), a cardiac‐enriched miRNA, is in most close relation to heart conditions, and the changes in its expression have been discovered in a variety of heart diseases 6, 7, 8, 9, 10.…”

CELF1 regulates gap junction integrity contributing to dilated cardiomyopathy

“…DCM is described as dilation of the left ventricle as well as impaired systolic function with a reduced ejection fraction (2,11). As DCM progresses, the left ventricle wall starts to thin and becomes weak, causing the heart to be inefficient at pumping blood to the systemic circulation (2).…”

Epigenetics for the pediatric cardiologist

“…Studies have shown not only association of epigenetic changes with heart failure, but also epigenetic changes associated with reverse remodeling after treatment with a beta blocker or left ventricular assist device. 35,36 Miyamoto et al also showed that circulating miRs are differentially expressed between children with dilated cardiomyopathy who recover versus those requiring a transplant. 37 These differences may represent a valuable biomarker for risk stratification, as well as a potential molecular therapeutic target.…”